News

Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease
The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...
Zacks Investment Research on MSN2d
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent ...
Stocktwits on MSN2d
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) ...
Medical Dialogues8h
FDA Approves Dupilumab as First Targeted Treatment for Bullous Pemphigoid
The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...
pharmaphorum2d
Dupixent is first FDA-approved drug for rare skin disease
IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder
Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease ...
Healio2d
FDA approves Dupixent for bullous pemphigoid
The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with ...
The American Journal of Managed Care2d
FDA Expands Dupilumab Approval as First New Biologic for Bullous Pemphigoid
Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...
Dupixent® (Dupilumab) Approved In The U.S. As The Only Targeted Medicine To Treat Patients With Bullous Pemphigoid (BP)
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use co ...
Nasdaq2d
Regeneron and Sanofi Announce FDA Approval of Dupixent for Treatment of Bullous Pemphigoid in Adults
Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “Dupixent has shown the potential to improve the most ...
Nasdaq2d
Regeneron, Sanofi: FDA Approves Dupixent To Treat Adult Patients With Bullous Pemphigoid
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and French drug major Sanofi S.A. (SNYNF,SNY) announced Friday that the U.S. Food and Drug Administration has approved Dupixent (dupilumab ...
PharmExec2d
FDA Approves Regeneron, Sanofi’s Dupixent for Bullous Pemphigoid
FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first and only targeted ...